Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study

Ju，Chunrong1; Wang，Xiaohua1; Xu，Xin1; Xie，Shaobo1; Cao，Qingdong2; Lin，Wanli3; Zhang，Jianheng1; Xu，Yu1; Lian，Qiaoyan1; Huang，Danxia1; Chen，Rongchang4; He，Jianxing1

2022-12-01

10.1186/s12879-022-07853-x

BMC Infectious Diseases   Impact Factor & Quartile

1471-2334

Background: Cytomegalovirus (CMV) infection is a leading cause of morbidity and mortality after transplantation. This study aimed to investigate CMV seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients. Methods: The clinical data of the patients who underwent lung and/or heart transplantation between January 2015 and October 2020 were retrospectively collected from four transplantation centers in China. Results: A total of 308 patients were analyzed. The CMV serostatus was donor positive (D) recipient negative (R) in 19 (6.17%) patients, D/R in 233 (75.65%), D/R in 36 (11.69%), and D/R in 20 (6.50%). CMV DNAemia was detected in 52.3% of the patients and tissue-invasive CMV disease was diagnosed in 16.2% of the patients. Only 31.8% of the patients adhered to the postdischarge valganciclovir therapy. The D/R serostatus (odds ratio [OR]: 18.32; 95% confidence interval [CI]:1.80-188.68), no valganciclovir prophylaxis (OR: 2.64; 95% CI: 1.05–6.64), and higher doses of rabbit anti-human thymocyte globulin (> 2 mg/kg) (OR: 4.25; 95% CI: 1.92–9.42) were risk factors of CMV disease. Conclusion: CMV seroprevalence was high in Chinese thoracic organ transplant donors and recipients. The low adherence rate to the postdischarge CMV prophylaxis therapy in Chinese patients is still an unresolved issue.

Cytomegalovirus Pneumonia Seroprevalence Thoracic organ transplant Valganciclovir

SCI

English

Corresponding

Natural Science Foundation of Guangdong Province[2018A030313107];State Key Laboratory of Respiratory Disease[SKLRD-QN-201710];

Infectious Diseases

Infectious Diseases

WOS:000886964000007

BMC

2-s2.0-85142263797

Scopus

1.Guangzhou Institute of Respiratory Health,First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Yanjiang Road,China
2.Department of Thoracic Surgery and Lung Transplantation,Fifth Affiliated Hospital of Sun Yat-sen University,Zhuhai,China
3.Department of Thoracic Surgery,The People’s Hospital of Gaozhou,Gaozhou,China
4.Shenzhen People’s Hospital Institute of Respiratory Diseases,Southern University of Science and Technology,University of Jinan Second Clinical Medical College,Shenzhen,East of Shennan Road, Luohu District,China

Ju，Chunrong,Wang，Xiaohua,Xu，Xin,et al. Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study[J]. BMC Infectious Diseases,2022,22(1).

Ju，Chunrong.,Wang，Xiaohua.,Xu，Xin.,Xie，Shaobo.,Cao，Qingdong.,...&He，Jianxing.(2022).Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study.BMC Infectious Diseases,22(1).

Ju，Chunrong,et al."Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study".BMC Infectious Diseases 22.1(2022).